Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

LPCN 1111: A Novel Next Generation Oral Testosterone Therapy Product with Potential for Once Daily Dosing

LPCN 1111 is a novel ester prodrug of testosterone which uses the Lip'ral technology to enhance solubility and improve systemic absorption. A Phase 1 single dose randomized, open label, crossover study in postmenopausal women has been completed and the pharmacokinetics suggested feasibility of once-daily dosing. Further, a Phase 2a study established once-daily dosing potential in hypogonadal men.

Clinical Trials